Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (780 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A progressive, degenerative neurologic disease characterized by a tremor that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. lewy bodies are present in the substantia nigra and locus coeruleus but may also be found in a related condition (lewy body disease, diffuse) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Idiopathic Parkinson Disease; Idiopathic Parkinson's Disease; Lewy Body Parkinson Disease; Lewy Body Parkinson's Disease; Paralysis Agitans; Parkinson Disease, Idiopathic; Parkinson's Disease; Parkinson's Disease, Idiopathic.
Where it fits in the MeSH classification
- Broader topics
- Parkinsonian Disorders; Synucleinopathies
- See also
- Lewy Bodies
Related concepts
- Tremor
- Lewy Bodies
- Lewy Body Disease
- Diffuse
Research landscape
PubMed indexes 96,962 records tagged with the MeSH heading “Parkinson Disease” (counts retrieved 2026-10-29). 30,221 of them (31.2%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 31,236 records.
Reviews account for 20,160 records (20.8%) and meta-analyses for 1,724. Randomized controlled trials number 2,941 (3.0%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 17,900 |
| 2000-2009 | 17,605 |
| 2010-2019 | 31,236 |
| 2020 onward | 30,221 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 20,160 | 20.8% |
| Meta-analyses | 1,724 | 1.8% |
| Randomized controlled trials | 2,941 | 3.0% |
Method: PubMed query "Parkinson Disease"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in neuroscience
Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Parkinson's disease (PD) is defined pathologically by loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc).
- Closing excerpt
- Together, these findings highlight a subtype-specific, cell-autonomous mechanism by which pathogenic LRRK2 impairs PD-vulnerable nigrostriatal synapses and provide a framework for therapeutic strategies targeting early synaptic deficits in PD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (156 words)
Parkinson's disease (PD) is defined pathologically by loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc). Yet synaptic dysfunction emerges much earlier, making it essential to define the mechanisms that drive early nigrostriatal deregulation. In the SNc, molecularly distinct dopamine neuron subtypes show differential susceptibility to PD. Here, we used intersectional genetic mouse models to determine how the PD-linked kinase LRRK2 affects vulnerable dopamine subtypes. Immunofluorescence and proximity-labeling proteomics revealed enriched LRRK2 expression in vulnerable dopamine neuron subclusters. High-resolution imaging showed that pathogenic LRRK2 disrupts presynaptic release-site organization in vulnerable dopamine axons, leading to reduced spontaneous and evoked striatal dopamine release in vivo. Proteomic analyses further showed that mutant LRRK2 increases phosphorylation of RAB3 proteins, impairing their interaction with the active-zone effectors RIM1 and RIM2. Together, these findings highlight a subtype-specific, cell-autonomous mechanism by which pathogenic LRRK2 impairs PD-vulnerable nigrostriatal synapses and provide a framework for therapeutic strategies targeting early synaptic deficits in PD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42660892 · DOI · PMC13522591
Lactate dynamics in Parkinson's disease: striatal circuit vulnerability, biomarker potential, and therapeutic windows [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Lactate is a mobile carbon substrate, extracellular signal, and candidate mediator of metabolism-to-gene coupling.
- Closing excerpt
- This framework defines lactate kinetics, compartment, and disease context as the critical variables for biomarker-guided rehabilitation and future PD trials.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (242 words)
Lactate is a mobile carbon substrate, extracellular signal, and candidate mediator of metabolism-to-gene coupling. These properties make lactate relevant to Parkinson's disease (PD), but current evidence does not support a simple protective or toxic interpretation. In this Review, we synthesize evidence that lactate dynamics may influence PD-relevant striatal biology through substrate provision, redox-sensitive NMDAR-ERK/MAPK-CREB signaling, HCAR1-mediated receptor signaling, and the emerging lactylation-linked modification of inflammatory or transcriptional states. We explicitly distinguish established non-PD mechanisms from direct PD-model evidence and from hypotheses that remain untested in D2 medium spiny neurons (D2-MSNs). We propose that the apparent lactate paradox in PD is best understood as a kinetic and compartmental problem: transient, well-cleared lactate pulses, such as those produced during exercise, may support metabolic flexibility, neurovascular adaptation, and selected forms of plasticity, whereas sustained lactate accumulation in mitochondrially constrained or inflammatory environments may promote acid-ion stress, oxidative injury, neuroimmune activation, and impaired dopaminergic signaling. The D2-MSN axis is therefore presented not as a proven site of lactate-mediated rescue, but as a high-priority experimental test bed for linking lactate dynamics to hypokinetic network states. Translationally, lactate is unlikely to serve as a stand-alone diagnostic biomarker. Its more realistic near-term uses are as a pharmacodynamic readout, a challenge-response variable for exercise dosing, and a target-engagement marker for interventions that modify lactate transport, signaling, or inflammatory metabolic state. This framework defines lactate kinetics, compartment, and disease context as the critical variables for biomarker-guided rehabilitation and future PD trials.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42410540 · DOI · PMC13504829
Activation of transposable elements is linked to a region- and cell type-specific interferon response in Parkinson's disease [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Parkinson's disease (PD) is a neurodegenerative disorder involving a neuroinflammatory response, the cause of which remains unclear.
- Closing excerpt
- Our findings provide insights into TE transcription in the PD brain and suggest that TEs may contribute to neuroinflammation and pathological progression in PD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (163 words)
Parkinson's disease (PD) is a neurodegenerative disorder involving a neuroinflammatory response, the cause of which remains unclear. Transposable elements (TEs) have been linked to inflammation, but their potential role in PD remains unexplored. Using bulk- and single-nuclei RNA-seq of postmortem brain tissue from four brain regions, we studied TE transcription and its correlation with PD neuroinflammation. Over a thousand TEs, including LINE-1 s and ERVs, were expressed in a cell type- and region-specific manner in the human brain. Increased TE expression was found in microglia and neurons in the substantia nigra and putamen of PD brains, but not amygdala or prefrontal cortex, compared to controls. This TE activation correlated with an innate immune response in the same brain regions. The link between an interferon response and TE activation was mechanistically confirmed using human pluripotent stem cell-derived microglia and neurons. Our findings provide insights into TE transcription in the PD brain and suggest that TEs may contribute to neuroinflammation and pathological progression in PD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42685224 · DOI · PMC13537272
Nitric oxide signaling and mitophagy in Parkinson's disease: implications for aerobic exercise-related neuroprotection [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Parkinson's disease is strongly associated with mitochondrial dysfunction and impaired mitochondrial quality control, including defective mitophagy.
- Closing excerpt
- Overall, aerobic exercise is a plausible modulator of mitophagy-related pathways in Parkinson's disease, and nitric oxide is a credible contributor to this effect; however, the current evidence supports a multi-node, context-dependent model rather than a simple linear mechanism.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (219 words)
Parkinson's disease is strongly associated with mitochondrial dysfunction and impaired mitochondrial quality control, including defective mitophagy. Aerobic exercise is increasingly recognized as a safe and accessible intervention that can improve motor and non-motor outcomes in Parkinson's disease and may also engage mechanisms relevant to disease modification. In this review, we propose a context-dependent framework in which aerobic exercise reshapes nitric oxide signaling toward a more adaptive profile, characterized by relatively moderate, transient, and spatially restricted nitric oxide bioactivity, and we discuss how this shift may influence mitochondrial biogenesis, mitophagy initiation, and autophagic flux regulation. Rather than treating nitric oxide as uniformly protective or deleterious, we argue that its biological effects in Parkinson's disease depend on source, concentration, duration, subcellular localization, cellular target, and surrounding redox milieu. However, direct evidence that exercise-derived nitric oxide activates these pathways in Parkinson's disease-relevant neural tissue is still limited. We further highlight major translational gaps, including cell-type and brain-region heterogeneity, incomplete definition of exercise dose-response relationships, and the lack of validated in vivo biomarkers of neuronal mitophagy and nitric oxide dynamics in patients with Parkinson's disease. Overall, aerobic exercise is a plausible modulator of mitophagy-related pathways in Parkinson's disease, and nitric oxide is a credible contributor to this effect; however, the current evidence supports a multi-node, context-dependent model rather than a simple linear mechanism.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42734454 · DOI · PMC13667388
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Multi-ancestry genome-wide association meta-analysis of Parkinson's disease [5]
- Research article Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis [6]
- Research article Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study [7]
- Research article Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis [8]
- Research article A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson's disease [9]
- Research article Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis [10]
References
- Chen C, He Q, Tombesi G, Napier E, Jaconelli M, Moreno-Ramos OA, et al.. Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons. . 2026. PMID 42660892 · DOI · PMC13522591
- Kong J, Yang Z, Wang Y, Liu L, Liu Y, Chen W. Lactate dynamics in Parkinson's disease: striatal circuit vulnerability, biomarker potential, and therapeutic windows. . 2026. PMID 42410540 · DOI · PMC13504829
- Garza R, Adami A, Thiruvalluvan A, Wijesinghe S, Curle A, Tam O, et al.. Activation of transposable elements is linked to a region- and cell type-specific interferon response in Parkinson's disease. . 2026. PMID 42685224 · DOI · PMC13537272
- Zhou Y, Wu Y. Nitric oxide signaling and mitophagy in Parkinson's disease: implications for aerobic exercise-related neuroprotection. . 2027. PMID 42734454 · DOI · PMC13667388
- Kim JJ, Vitale D, Otani DV, Lian MM, Heilbron K, 23andMe Research Team, et al.. Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. Nat Genet. 2024. PMID 38155330 · DOI · PMC10786718
- Zhu J, Cui Y, Zhang J, Yan R, Su D, Zhao D, et al.. Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 2024. PMID 38945129 · DOI
- Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, et al.. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023. PMID 37633302 · DOI · PMC10593199
- Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, et al.. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024. PMID 38588457 · DOI · PMC11001292
- Kwon SH, Park JK, Koh YH. A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson's disease. J Neuroeng Rehabil. 2023. PMID 37475014 · DOI · PMC10360300
- d'Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. 2023. PMID 37358841 · DOI · PMC10294019
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.